^
    Back
    Association details:
    Biomarker:CD22 expression
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) +
    Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    Excerpt:
    ...- CD22-positive disease defined as CD22 expression by >= 20% of lymphoblasts by local hematopathology evaluation....
    Trial ID:
    A041703
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.

    Published date:
    05/25/2023
    Excerpt:
    Eligible were pts ≥60 years old with ND, Ph-, CD22+ (≥20% of blasts) B-ALL...The cumulative CR rates through Course IA/B/C and Course II were 85% and 97%, respectively...InO induction then blina consolidation is highly active for ND, Ph-, CD22+ B-ALL. The regimen is an option for older adults and a comparator regimen for future studies.
    DOI:
    10.1200/JCO.2023.41.16_suppl.7006
    Trial ID:
    A041703